ReAlta Life Sciences is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare and seriously debilitating diseases.
We currently have a clinical stage investigational medicine in our product pipeline indicated for Hypoxic Ischemic Encephalopathy (HIE) (NCT05778188), Acute Graft versus Host Disease (NCT06343792), and Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) (NCT06175065). Our goal, whenever possible, is to encourage patients to participate in clinical trials. Clinical trials are research studies designed to determine if an investigational medicine is safe and effective for patients. We do recognize that some patients will not be eligible for our clinical trials, or will not be near a participating provider, and may wish to access our product candidates through expanded access (also known as compassionate use) if they have exhausted all available medical options. However, currently, we do not offer expanded access use of our investigational medicines. ReAlta Life Sciences may revise this expanded access policy at any time. The posting of this policy by ReAlta Life Sciences does not serve as a guarantee of access to any specific investigational medicine by any individual patient.
If you have any questions, please reach out to us at info@ReAltaLifeSciences.com.
Last revised August 9, 2024.